Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis

Highlights • ICT provides no additional benefit to OS, DFS, and DM endpoints for OSCC survival. • LRR may be improved with the addition of ICT in OSCC treatment. • A cumulative meta-analysis is an effective tool to visualize and identify survival trends over time.

Saved in:
Bibliographic Details
Published inOral oncology Vol. 61; pp. 104 - 114
Main Authors Lau, Ashley, MBBS, BSc, Li, Kar-Yan, MPhil, BSc, Yang, Wei-fa, DDS, Su, Yu-Xiong, MD, DDS
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2016
Subjects
Adjuvant chemotherapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - administration & dosage
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Cisplatin - administration & dosage
Hematology, Oncology and Palliative Medicine
Humans
Induction Chemotherapy
Meta-analysis
Mouth neoplasm
Mouth Neoplasms - drug therapy
Mouth Neoplasms - pathology
Oral cancers
Otolaryngology
Survival Analysis
Systematic review
Mouth neoplasm
Systematic review
Induction chemotherapy
Adjuvant chemotherapy
Oral cancers
Meta-analysis
Online AccessGet full text

Cover

More Information
Summary:Highlights • ICT provides no additional benefit to OS, DFS, and DM endpoints for OSCC survival. • LRR may be improved with the addition of ICT in OSCC treatment. • A cumulative meta-analysis is an effective tool to visualize and identify survival trends over time.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2016.08.022